Novartis AG (NVSEF) stock
NVSEFOTCPharmaceutical PreparationsFiscal year ends December 31Also trades as NVS
$146.46+2.56 (+1.78%)
Close on Oct 19, 2026Market cap $279.46BP/E 20.5Yield –
Novartis net income
Net income is the profit left for shareholders after every expense, interest and tax.
For fiscal 2025 it was $13.98B, up 17.1% from the year before. Over ten years it grew -2.4% a year on average. The highest annual figure on record is $24.02B in fiscal 2021.
Annual net income
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $13.98B | +17.1% |
| FY2024 | Dec 31, 2024 | $11.94B | -19.6% |
| FY2023 | Dec 31, 2023 | $14.85B | +113.5% |
| FY2022 | Dec 31, 2022 | $6.96B | -71.0% |
| FY2021 | Dec 31, 2021 | $24.02B | +197.6% |
| FY2020 | Dec 31, 2020 | $8.07B | -31.2% |
| FY2019 | Dec 31, 2019 | $11.73B | -7.0% |
| FY2018 | Dec 31, 2018 | $12.61B | +63.7% |
| FY2017 | Dec 31, 2017 | $7.70B | +14.8% |
| FY2016 | Dec 31, 2016 | $6.71B | -62.3% |
| FY2015 | Dec 31, 2015 | $17.78B | – |
Quarterly net income
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $3.26B | +92.7% |
| Q2 FY2025 | Jun 30, 2025 | $4.04B | +39.5% |
| Q2 FY2024 | Jun 30, 2024 | $3.25B | +73.9% |
| Q2 FY2023 | Jun 30, 2023 | $2.32B | -65.9% |
| Q2 FY2022 | Jun 30, 2022 | $1.69B | -78.2% |
| Q2 FY2021 | Jun 30, 2021 | $2.90B | +46.3% |
| Q2 FY2020 | Jun 30, 2020 | $1.87B | – |
| Q2 FY2019 | Jun 30, 2019 | $6.80B | – |
| Q2 FY2018 | Jun 30, 2018 | $7.77B | – |
| Q2 FY2017 | Jun 30, 2017 | $1.98B | – |
See a number that looks wrong?